Navigating modern preclinical research requires uncompromising analytical documentation. A laboratory-grade Cagrilintide Certificate of Analysis (COA) provides critical baseline data confirming sequence identity, structural purity, and freedom from biological contaminants. PX1 Research delivers lot-specific third-party verification to ensure your experimental assays yield precise, reproducible scientific results.
Navigating modern preclinical research requires uncompromising analytical documentation. A laboratory-grade Cagrilintide Certificate of Analysis (COA) provides critical baseline data confirming sequence identity, structural purity, and freedom from biological contaminants. PX1 Research delivers lot-specific third-party verification to ensure your experimental assays yield precise, reproducible scientific results.
A Cagrilintide Certificate of Analysis (COA) is an official analytical report generated by an independent, accredited laboratory to verify the identity, structural integrity, purity, and microbial safety of a specific peptide production lot. It details core metrics including Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) purity percentage (typically targeting >98%), Mass Spectrometry (MS) molecular weight confirmation, residual solvent analysis, and bacterial endotoxin levels.
For investigators procuring synthetic compounds through our all-peptides library, reviewing the lot-specific COA is an essential step prior to initiating in vitro assays or preclinical animal studies. The COA serves as a quantitative guarantee that the research material is free from synthesis byproducts, truncated peptide sequences, and bioburden that could otherwise introduce confounding variables into receptor binding studies or metabolic research models.
Cagrilintide is an acylated, long-acting synthetic lipopeptide designed to function as a non-selective agonist of human amylin receptors (AMYR1, AMYR2, and AMYR3) as well as the calcitonin receptor (CTR). Structurally modeled after native human amylin (islet amyloid polypeptide or IAPP), cagrilintide incorporates deliberate amino acid substitutions and a C16 or C18 fatty acid side chain connected via a hydrophilic spacer. These structural modifications impair self-aggregation while extending its circulating plasma half-life in rodent models.
In basic biochemical research, the structural integrity of this lipidated chain is paramount. Any degradation or premature cleavage of the acylated moiety alters its target binding kinetics at the calcitonin receptor core complex. Consequently, confirming molecular weight through mass spectrometry on the cagrilintide certificate of analysis ensures that the acylated side chain remains fully intact prior to experimental reconstitution.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the gold standard method for determining the chemical purity of synthetic peptides. The RP-HPLC section of a cagrilintide COA displays a chromatogram showing optical density measured at 214 nm or 220 nm—wavelengths corresponding to the absorption of peptide bonds.
A target purity of ≥98.0% indicates that the main peak accounts for at least 98% of the total integrated peak area. Minor satellite peaks represent minor impurities, such as single-amino-acid deletions, incomplete acylation, or oxidation products (e.g., methionine sulfoxide). In rigorous scientific settings, understanding these peak distributions prevents erroneous interpretation of downstream signaling assays. For a detailed primer on chromatogram evaluation, explore our technical guide on peptide purity testing using HPLC and MS.
While HPLC quantifies purity by separating chemical species, Mass Spectrometry (MS)—typically Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) or Electrospray Ionization (ESI-MS)—verifies the exact molecular mass of the target peptide. The expected theoretical monoisotopic or average mass of cagrilintide must match the observed mass peak within a tight tolerance (usually ±1.0 Da).
Mass spec data included on every PX1 Research COA rules out structural errors such as incorrect amino acid sequence coupling, incorrect disulfide bridge formation, or incomplete deprotection during solid-phase peptide synthesis (SPPS). When cross-referencing MS data with the compound's theoretical mass, researchers can confidently confirm that the material present in the vial matches the exact chemical structure requested.
Bacterial endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—pose a significant risk in preclinical animal models and cell culture experiments. Endotoxins can activate Toll-like receptor 4 (TLR4), triggering unwanted inflammatory signaling pathways, cytokine release, and cellular toxicity that completely mask or skew the true biological activity of the compound under evaluation.
A rigorous cagrilintide COA reports endotoxin levels measured via the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C (rFC) assay. PX1 Research enforces strict endotoxin thresholds (typically <0.01 EU/μg or <0.1 EU/mg depending on assay requirements), ensuring that high-purity research compounds ordered through our wholesale or laboratory accounts do not introduce confounding immunogenic artifacts into sensitive physiological studies.
In preclinical metabolic research, cagrilintide is extensively studied for its distinct mechanism of action relative to incretin mimetics. While traditional GLP-1 receptor agonists target gastrointestinal and hypothalamic pathways regulating glucose-dependent insulin secretion, dual amylin/calcitonin receptor agonists modulate central satiety circuits in the area postrema and nucleus of the solitary tract (NST).
Animal model data demonstrate that cagrilintide administration leads to sustained dose-dependent reductions in food intake, delayed gastric emptying, and improved lipid utilization. Researchers frequently investigate cagrilintide alongside other metabolic probes in dual-agonist paradigms. In-depth analysis of these cellular pathways can be reviewed in our research library hub.
When designing multi-pathway metabolic trials, researchers often compare or combine amylin analogs with incretin receptor agonists to study synergistic weight regulation and glycemic control. The structural and functional differences among these primary metabolic research compounds are highlighted below:
Cagrilintide acts as a long-acting amylin and calcitonin receptor agonist, targeting central satiety centers independent of direct insulin secretagogue pathways. In contrast, mono-incretins like semaglutide selectively activate the GLP-1 receptor to augment glucose-dependent insulin secretion and slow gastric motility. Multi-receptor co-agonists like tirzepatide combine GLP-1 and GIP receptor activation, while early-generation amylin mimetics like pramlintide lack the lipid acylation required for extended half-life in longitudinal rodent models. Ensuring lot consistency across each distinct compound class via lot-specific COAs is vital when attempting to isolate complementary receptor signaling mechanisms.
To preserve the structural purity verified on the COA, researchers must follow strict storage and handling protocols upon receipt of lyophilized cagrilintide. Prior to reconstitution, unopened vials should be stored in a freezer at -20°C (or -80°C for long-term storage) protected from light and moisture desiccation.
When preparing solutions for laboratory assays, allow the vial to equilibrate to room temperature before adding sterile bacteriostatic water or target-appropriate buffer solutions. Avoid high-shear agitation or excessive vortexing, which can induce peptide aggregation or shear lipid chains. Detailed reconstituting instructions, diluent selection matrices, and stability windows can be found in our technical guide for reconstitution and storage guidelines.
When validating a Cagrilintide Certificate of Analysis from any research supplier, laboratory managers and scientific auditors should verify the presence of seven core data points:
1. Manufacturer Lot Number matching the physical vial label. 2. Date of Analytical Testing and report issuance. 3. Independent Third-Party Testing Laboratory credentials (ISO 17025 accreditation). 4. RP-HPLC Chromatogram displaying baseline resolution and numerical integration tables (≥98.0% purity). 5. Mass Spectrometry Spectrum confirming theoretical mass within defined molecular tolerance. 6. Quantitative Endotoxin Data (LAL assay result reported in EU/mg). 7. Physical appearance verification (e.g., white to off-white lyophilized powder).
PX1 Research maintains an uncompromising commitment to analytical transparency. Every single lot of cagrilintide and related research compounds is synthesized in US-based, GMP-compliant facilities and subjected to rigorous third-party verification at accredited ISO 17025 testing laboratories.
We publish lot-specific COAs for full public download, allowing research teams to audit raw RP-HPLC chromatograms, mass spectra, and bioburden data before placing an order. Coupled with same-day shipping from our California and Arizona fulfillment centers, PX1 Research provides the quality control foundation necessary for reproducible laboratory science.
What purity level should a Cagrilintide COA show for valid in vitro research?
For reliable in vitro and preclinical research, a Cagrilintide COA should demonstrate an RP-HPLC purity of ≥98.0%. High purity minimizes the presence of truncated peptide fragments or acylation byproducts that could interact non-specifically with amylin or calcitonin receptors.
How do I match a physical vial of Cagrilintide to its Certificate of Analysis?
Every PX1 Research vial features a printed lot number on its label. Cross-reference this lot number directly with the COA document published in our analytical database to ensure you are reviewing the precise testing data for your specific batch.
What analytical technique is used to confirm Cagrilintide identity on the COA?
Mass Spectrometry (MS)—typically ESI-MS or MALDI-TOF—is used to confirm molecular identity by measuring the exact mass-to-charge ratio of the compound, matching it against the theoretical molecular weight of acylated cagrilintide.
What is the acceptable endotoxin threshold on a Cagrilintide COA?
For general preclinical laboratory research, endotoxin levels measured via LAL assay should ideally fall below 0.01 EU/μg (<10 EU/mg). Minimal endotoxin contamination prevents inflammatory receptor activation in cellular and animal models.
Why is third-party COA testing critical for research peptides?
In-house supplier reports may suffer from selective reporting or batch averaging. Third-party testing by an accredited ISO 17025 laboratory provides an unbiased analytical evaluation of peptide purity, identity, and bioburden.
Does lyophilized Cagrilintide require immediate refrigeration upon arrival?
Lyophilized cagrilintide is stable at ambient temperatures during short-term transit, but upon delivery, vials should be stored at -20°C or lower to ensure long-term stability and prevent hydrolytic degradation.
Can I obtain wholesale batch testing for bulk Cagrilintide orders?
Yes. Institutional accounts purchasing through our wholesale portal receive full, lot-specific third-party testing packages, including raw chromatograms and MS spectra for every bulk batch supplied.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.